Drugs / AXT-1003
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06484985 | Sep 2024 → Mar 2027 expected | non-Hodgkin lymphoma | Axter Therapeutics (Beijing) Co., Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT05965505 | Aug → Sep 2023 | non-Hodgkin lymphoma | Axter Therapeutics (Beijing) Co., Ltd | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AXT-1003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06484985 ↗ |
| Route | Oral | “AXT-1003 capsule is administered orally daily, until disease progression or intolerable toxicity.” NCT05965505 ↗ |